Health Care [ 9/12 ] | Health Care Equipment & Supplies [ 56/74 ]
NASDAQ | Common Stock
Aclarion, Inc. operates as a healthcare technology company in the United States.
The company uses magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments.
It develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine.
The company also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and data transfer products, including AMBRA Healthcare, an imaging data transfer platform and NOCIWEB, a custom developed web-interface.
In addition, it offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient.
The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021.
Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 26, 25 | -1.63 K Decreased by -106.11 K% | -1.36 K Decreased by -20.00% |
| Nov 27, 24 | -1.36 K Decreased by -1.16 M% | -1.63 K Increased by +16.67% |
| Aug 23, 24 | -1.36 K Decreased by -904.39 K% | -2.08 K Increased by +34.78% |
| May 15, 24 | -0.44 Decreased by -340.00% | -0.57 Increased by +22.81% |
| Feb 20, 24 | -1.53 Decreased by -801.71% | -1.60 Increased by +4.19% |
| Nov 14, 23 | -0.12 Increased by +44.29% | -0.09 Decreased by -30.00% |
| Jul 3, 23 | -0.15 Increased by +69.39% | -0.10 Decreased by -50.00% |
| May 31, 23 | -0.10 Increased by +92.59% | -0.10 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 10.23 K Increased by +1.17% | -1.99 M Increased by +17.07% | Decreased by -19.44 K% Increased by +18.03% |
| Dec 31, 24 | 10.23 K Decreased by -25.84% | -1.99 M Decreased by -57.24% | Decreased by -19.44 K% Decreased by -112.02% |
| Sep 30, 24 | 14.41 K Decreased by -24.43% | -1.37 M Decreased by -36.89% | Decreased by -9.48 K% Decreased by -81.15% |
| Jun 30, 24 | 10.97 K Decreased by -35.74% | -1.24 M Increased by +15.46% | Decreased by -11.28 K% Decreased by -31.55% |
| Mar 31, 24 | 10.11 K Decreased by -60.29% | -2.40 M Decreased by -102.72% | Decreased by -23.72 K% Decreased by -410.51% |
| Dec 31, 23 | 13.80 K Decreased by -38.73% | -1.27 M Increased by +4.88% | Decreased by -9.17 K% Decreased by -55.26% |
| Sep 30, 23 | 19.07 K Increased by +4.63% | -998.01 K Increased by +38.88% | Decreased by -5.23 K% Increased by +41.58% |
| Jun 30, 23 | 17.07 K Increased by +59.91% | -1.46 M Increased by +60.50% | Decreased by -8.58 K% Increased by +75.30% |